Ive got a foot in both camps here. Yours & Buffetts.
I agree with you that Biota's revenues have been sporadic.
But as Buffett says their revenue will increase substantially.
They have been essentially a one product company and realistically, without the global scare of bird flu would be struggling. Relenza was pretty much dead in the water.
The swine flu will spread, that is almost a certainty. The media have got hold of this as a world event and will keep it on the front page as more outbreaks occur. Whether it is a particularly dangerous strain is yet to be determined.
Irrespective of this governments throughout the world are stocking up on antivirals
Therefore for the next year or so BTAs revenue will be substantial, and guaranteed.
After that ( maybe ?) there is their new long acting antiviral LANI.
So at present prices ( around $1.40 ) I see more short to midterm upside than downside.
Cheers
Bendigo
BTA Price at posting:
$1.38 Sentiment: None Disclosure: Held